



Merck Statement on the APPROVe Extension Statistical Package

On May 11, 2006, Merck & Co., Inc. announced the preliminary analyses of the off-drug extension of the APPROVe study. In addition to the press release announcement and accompanying summary report, Merck is making available a copy of the APPROVe Extension Statistical Package submitted to regulatory agencies.

The APPROVe Extension Statistical Package supports previous statements made by the Company regarding the preliminary analyses of the off-drug extension of the APPROVe study.

For additional information regarding all of the findings from the off-drug extension of the APPROVe study, please visit the VIOXX Information Center on www.merck.com for the Company's press release, summary report and APPROVe extension statistical package.

Forward-Looking Statement

This statement contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential or financial performance. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this statement should be evaluated together with the many uncertainties that affect Merck's business, particularly those mentioned in the cautionary statements in Item 1 of Merck's Form 10-K for the year ended Dec. 31, 2005, and in its periodic reports on Form 10-Q and Form 8-K, which the Company incorporates by reference.

#